Eden Research Share Discussion Threads

[investingisatrickygame] 08/5/2021 10:18

Someone found a good reason to invest in Eden


Date Time Trade Prc Volume Buy/Sell Bid Ask Value
06-May-21 15:58:04 15.05 333,687 Buy* 14.50 15.20 50.22k

[supersonico] 07/5/2021 10:51

Church Timetable news.

So the Metaldehyde slug pellet ban kicks in March 2022 and Bayer etal neonicotinoids are getting hit.

We're waiting, infested, for TT.

The question as per usual for Blakey, UN and SO is do they all come at once like parallel buses or do they each go their own Fleetwood way?

What ever happens regulation is pushing them into Eden's neck of the depot.
......................

Eden SustainE video posted on EASTMAN youtube channel

[supersonico] 07/5/2021 09:58

European Court of Justice dismissed Bayer's appeal in its challenge against the EU restrictions on neonics

[wilmer100] 07/5/2021 08:05

https://www.mirror.co.uk/tv/tv-news/dragons-den-viewers-cant-stop-24057025Strange how this lady can get her head lice treatment to market and where's Eden's?

[timbo_slice] 06/5/2021 18:28

It's unbelievable.... hahahahahahaha

[neutralpov] 06/5/2021 17:33

And where are the profits?
(chuckle)
Dividends???
(lol)
Only for the BoD. They call it "remuneration".
(guffaw)


QUIZ!
-- Halfwits. Suckers. Losers. EDEN shareholders.
Find the odd one out.

[neutralpov] 06/5/2021 17:27

Chrischas 1 May '21 9258
> Corteva seems dead in the water

Bingo

[weyweyumfozo] 06/5/2021 16:34

I see that dopey has been talking to himself on the other tread for two days.

It's like watching someone trying to start a fight in a telephone box.

[timbo_slice] 02/5/2021 13:19

Terremerse are on their own media platforms highlighting the benefits of 3Logy (Mevalone)... which then ties back in with this from Eden (see below) .... Terremerse must then be happy with the use and outcome... wonder what happens at the end of the 120 days ? 24 February 2021Emergency use approval in ItalyWe are happy to announce that 3logy™ (Mevalone®) has been granted emergency use approval in Italy in 2021 for use on a number of horticultural crop species to help tackle botrytis. This 120-day approval has been granted because farmers in Italy are challenged by the lack of registered products for the crops in question. This sort of approval is granted when growers demonstrate a clear need for such a use. Eden are pleased to be able to assist farmers with our sustainable products, which are an alternative to conventional chemicals and are particularly useful for growers focussed on production of residue free crops.CLOSE

[supersonico] 02/5/2021 10:16

Terremerse Soc. Coop.



3LOGY, a product based on eugenol, geranium and thymol, has obtained authorization for emergency uses (at a dosage of 4 l/ha for a maximum of 5 applications) on some horticultural crops, in particular: strawberry 🍓e small fruits, lettuces and salads, including baby leaf (including brassicaceae), solanacee (tomato🍅, pepper, eggplant🍆) and fennel.
3LOGY is a formulation for the preventive control of 📌sclerotin on horticultural crops and📌bothritis, adversity that can cause serious damage to the vine as well.
The strengths of 3LOGY:
🔹 Good activity against the diseases listed above,
🔹 Reduced safety interval of 1 day
🔹 use in both integrated and biological defense programs,
🔹Ability to intervene in the different phases of the cycle, including close to the collection of
🔹 Total absence of residues

[supersonico] 02/5/2021 09:09

If Chrishas has as good an idea about Eden's aquatic status as he has about Eden's competitors then I think it's safe to say he's talking Carp.

[investingisatrickygame] 01/5/2021 22:20

Chrischas

"Corteva seems dead in the water"

I think that is highly unlikely for reasons that attyg has pointed out before.

8/1/2020 The exclusive evaluation period for Corteva as per the 'agreement' RNS had an end date of 31/12/2020

28/2/2020 Placing RNS states

"Significantly for Eden, regulatory change led to the withdrawal of one of Corteva Agriscience's key seed treatment in the EU. Initial trials by Corteva Agriscience have shown strong results using Eden's products and formulation technology".

This implies to me that Sustaine will be the vehicle to bring this key seed treatment for Corteva back on sale in the territories mentioned.

14/10/2020 The Interims Presentation said

"Results to date are in-line with expectations"

11/2/2021 Year end trading update RNS said

"This process is currently moving forward, as expected, and the Company will provide an update as soon as practicable".

Then it further states "Additionally, this is the most comprehensive work done by to date on major broad-acre crops using Eden's technologies".

Finally, on the 1st of April, this year, the Company finally executed the granting of the new options under the Long-Term Incentive Plan which to my mind tells you what you need to know.

I doubt a "no deal" would support those options coming into play and to my mind this RNS confirms to me that Eden will indeed reach agreement with Corteva and up to €40 million per annum will be delivered to Eden's P & L in short order.

This deal alone, as stated many, many times, equates to a value far, far greater than 15pence per share.

[chrischas] 01/5/2021 16:41

Corteva seems dead in the water

[investingisatrickygame] 01/5/2021 14:06

SS said in 2020 that Eden is very advanced (as I recall it) with its insecticides development, yet we have heard nothing since. Might this be a discussion Eden is also having with Corteva?

If not with Corteva, how far have we now moved on and who might we build a relationship with to manufacture, market and sell?

Might we have news from Elanco soon? We must surely be due an update given there was only one formulation with Bayer to resolve.

What inroads has Doctor Michael Carroll made since his appointment on the 15th April 2020. We are over a year on and have never had a progress report from him He did state on Food For Thought the following

"I hope to help progress many of the pending authorisations we have in our pipeline. One of the big projects to note is the Mevalone and Cedroz authorisations in the United States. We are in the last stages of the federal authorisation which will allow states to give their own authorisations. We are currently actively working with EPA to answer their questions, and we are hoping to get a decision as soon as possible, ideally by the end of the year."

Given there are no sales without regulatory approval, I would say after Corteva then Dr Michael Carroll is the first person who should be updating Eden's shareholders as there is a lot of value pending in Cedroz and Mevalone. An update may give investors a reason to buy.

Also from the 24/6/2020 AGM Q & A it was stated

"We are also exploring additional opportunities with Corteva, and in seed treatments more widely, which we are pursuing both alone and in partnership".

How about an update on these other seed opportunities. With a year gone by, I don't think this is an unreasonable request and expectation.

[neutralpov] 30/4/2021 17:32

andysmall2 30 Apr '21 - 15:30 - 9252
> So why buy?

Dunno. Only a moron would. I'm not. (I get it that you must be addressing the eejit spadey).

This dog of a stock is good only for shorting.

Restated target price... 0p

[neutralpov] 30/4/2021 12:50

I'm not the one who's going to see his stock holding dwindle to a value of ZERO, loser. ;D

I know you w*nkers pay your bills with RNSs, quotes and cake-tomorrow.

The sane among us prefer ££.

1. Where's the divvies, wipes?

2. Why do you think the BoD is a charity, trying to make money for fickle strangers like you lot? If this was a bargain, they'd have bought up every last stray share.

(lol - and some of these dreggy double-digiters actually think that -I- am the troll)